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Neurophysiological testsAbstract Background: Central nervous system involvement in SLE as a part of neuropsychiatric
lupus is a complex diagnostic entity due to its multiple clinical presentations.
Objective: This study aimed to assess the value of susceptibility weighted imaging (SWI) and
neurophysiological assessment on 30 patients with SLE in order to determine the value in the early
diagnosis and management of neurological manifestation of lupus.
Materials and methods: Thirty patients with ACR criteria for SLE are involved in this study.
Antiphospholipid antibodies, SWI, and evoked response studies were used to assess neurological
involvement in SLE.
Results: Eighteen patients presented with clinical neurological manifestations attributed to neuro-
logical lupus. Abnormal SWI ﬁndings were found in 16 patients. 11 SLE patients were positive for
antiphospholipid. 17 patients presented with abnormal neurophysiological parameters. No correla-
tion between individual neurophysiological disorders (NPD) and speciﬁc neuropsychiatricpholipid
oo.com
166 H.M. Saad Allah et al.symptoms was observed. There was no signiﬁcant correlation between the electro physiologic ﬁnd-
ings and SLE related auto antibodies.
Conclusions: SWI and neurophysiological studies may provide a useful test in the evaluation and
management of early neurological lupus.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.Introduction
Systemic lupus erythematosus (SLE) is a chronic, autoim-
mune, multiorgan disease with a broad spectrum of clinical
manifestations. SLE with involvement of the central nervous
system (CNS), which is often called neuropsychiatric SLE
(NP-SLE), is one of the most important manifestations of
SLE.1 The condition may be both neurological and psycholog-
ical,2,3 and the reported prevalence of CNS involvement varies
in different studies.4–8 This probably reﬂects differences in pa-
tient selection, different criteria for NP-SLE, differences in the
neuropsychological tests used and the lack of standard diag-
nostic instruments for CNS manifestations.
The pathogenesis of CNS dysfunction in SLE is not well
understood. The observation of both diffuse and focal CNS
involvement in SLE has led to the hypothesis that there are
several pathogenic mechanisms in NP-SLE, such as micro vas-
cular damage, small-vessel vasculopathy and autoantibody-
mediated neuronal cell injury.9–12
Many biochemical and immunological studies have been
undertaken in an attempt to identify speciﬁc abnormalities which
might be helpful to the clinician.13 In addition, the value of
imaging techniques has been investigated.14 However, despite
considerable research, the management of neurological lupus
has not been facilitated by the emergence of sufﬁciently reliable
or practical investigative techniques. Neurophysiological tech-
niques havebeenof value in the assessmentof neurological symp-
toms occurring in other diseases such as multiple sclerosis.15,16
The aim of the present study was to assess the value of sus-
ceptibility weighted imaging (SWI) and neurophysiological
studies on thirty randomly selected patients with SLE in order
to determine whether this form of assessment might be of value
in the diagnosis and management of neuropsychiatric manifes-
tations of SLE and to correlate the radiological and electro-
physiological abnormalities with SLE related auto antibodies.Methods and patients
Thirty SLE patients were randomly selected from a population
attending the Department of Rheumatology. All patients
fulﬁlled the American Rheumatism Association, 1982 revised
criteria for SLE. A detailed history and clinical examination
of all patients were performed. The study also included 15
age and sex matched healthy control subjects. The entire pro-
tocol was approved by Human Ethics Committee of the Fac-
ulty of Medicine, Alexandria University, Egypt and informed
consent was obtained from each human subject prior to
participation.
Several investigations like autoantibody batteries [anti-
phospholipid antibodies (PA), anticardiolipin antibodies
(aCL) and lupus anticoagulant (LA)], susceptibility weighted
imaging (SWI), and electro diagnostic studies [somatosensoryevoked potential (SSEP), visual evoked potential (VEP) and
brain stem auditory evoked response (BAEP)] were all used
to study neuropsychiatric involvement in SLE.
Patients were evaluated with routine MRI sequences;
namely axial and sagittal T1-weighted images, axial and coro-
nal T2-weighted images and coronal T2-weighted images as
well as FLAIR sequences, in addition to susceptibility
weighted imaging. Studies were performed on a 1.5 T MRI
scanner (General Electric Medical Systems). T1-weighted
images were acquired utilizing 500/20/2 TR, TE, excitations,
256 · 256 matrixes, FOV of 20 cm, 6 mm slice thickness, and
0.6 mm inter-slice gap. The T2-weighted images were acquired
utilizing 4000/100/2 TR, TE, excitations, 256 · 256 matrixes,
FOV of 22 cm, 5 mm slice thickness and 0.5 mm inter-slice
gap. The SWI sequence parameters were TR/TE 500/30, num-
ber of excitations 2, ﬂip angle 20, 5 mm contiguous slices.17Statistical analysis
The data were collected and entered into the personal com-
puter. Statistical analysis was done using Statistical Package
for Social Sciences (SPSS/version 20) software.
Arithmetic mean, standard deviation, for more than two
groups ANOVA test was used. The level of signiﬁcance was
0.05.Results
The study included thirty SLE patients, the patient character-
istics are summarized in Table 1. The mean age of the patients
was 31.3 ± 9.9 years (range: 9–49).
Twenty-eight patients were females (93.3%), while two
patients were males (6.7%). The duration of SLE ranged be-
tween 1 and 20 years with a mean of 6.7 ± 4.9.
Hypertension was found in 11 patients (36.7%) and nephri-
tis was found in 6 patients (20%).
There were 18 (60%) patients who presented with deﬁnite
neuropsychiatric events and twelve (40%) patients were neuro-
logically free. Stroke was the most frequent neurological mani-
festation (7 patients), another 6 patients presented with
headachemostly migraines, 3 patients with psychosis, 3 patients
with epilepsy, two patients with mood disorder like depression,
and 3 patients with polyneuropathy. Six SLE patients had more
than one neuropsychiatric symptom. Seizures can occur at any
time during the course of the disease. Psychosis was found in the
younger age group (ranged between 12 and 29 years) while
patients with polyneuropathy were about 45 years of age.
Neuropsychiatric signs were signiﬁcantly present in patients
with hypertension (p= 0.02) and nephritis (p= 0.03).
The routine MR imaging sequences were relatively
insensitive for small micro hemorrhages resulting from under-
lying vasculopathy and only detecting the residual area of
Table 1 Patient characteristics and neuropsychiatric manifes-
tations in SLE.
Patient characteristics Number Percent
Age (years)
Range 9–49
Mean ± SD 31.3 ± 9.9
Sex
Male/female 2/28 6.7/93.3
Disease duration (years)
Range 1–20
Mean ± SD 6.7 ± 4.9
Positive clinical ﬁndings:
Hypertension 11 36.7
Nephritis 6 20.0
Neuropsychiatric complaints
Absent 12 40.0
Psychotic manifestation 3 10.0
Headache (migraine) 6 20.0
Mood disorder (depression) 2 6.7
Seizure disorders 3 10.0
Polymyositis 3 10.0
Cerebrovascular diseases 7 23.3
Total 30 100.0
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detection of areas of old micro hemorrhages and abnormal
vasculopathy resulting in the formation of hemosiderin that
causes local magnetic ﬁeld in homogeneity.
Abnormal SWI ﬁndings were found in 16 patients. Patients
with abnormal SWI were divided into 14 patients with focal
parenchyma lesions, 2 patients with brain atrophy. Patients
with focal parenchyma lesions were subdivided into 9 patients
with multiple lesions <1 cm located in the sub cortical white
matter (SSCL) and 5 cases with lesion >1 cm (infarcts). One
of these patients had mixed small sub cortical lesions and in-
farct. There was no statistical signiﬁcant difference between
the age of the patients and the abnormal SWI ﬁndings
(p= 0.36). Moreover, the duration of the disease did not differ
signiﬁcantly among those with normal or abnormal SWI
(p= 0.51).
The presence of abnormal radiological ﬁndings and the dis-
tribution of the different SWI categories were signiﬁcantly
more frequent in the hypertensive patients (p= 0.004,
p= 0.00, respectively). There were twelve (40%) patients with-
out neuropsychiatric manifestations but the SWI was abnor-
mal in 5 of them, 3 of them had small sub cortical lesions
and 2 had cortical cerebral atrophy (Figs. 1 and 2).
Assessment of SLE related auto antibodies revealed, eleven
SLE patients (37%) were PA positive. Of the patients with PA
positive, 5 (17%) had positive aCL and 3 (10%) had positive
LA and another 3 (10%) had both aCL and LA. The mean
age of patients with or without positive PA was not signiﬁ-
cantly different. The frequency of positive auto antibodies in
patients with vascular insults was higher than those without
but with no statistical signiﬁcant difference. The distribution
of immunoserological ﬁndings was different among the differ-
ent SWI categories (Table 2).As shown in Table 3, the mean evoked potential study
parameters were signiﬁcantly altered in SLE patients compared
to controls. Evoked potential abnormalities were detected in
seventeen patients (57%). In SLE patients with neuropsychiat-
ric symptoms, 12 patients out of 18 had neurophysiological
abnormalities as shown in the prolonged latencies and
diminished amplitudes in SSEP and VEP. Also, altered BAEP
as manifested by prolonged wave L1 absolute latency and
prolonged interpeak interval 111-V.
Abnormalities in the peripheral nerve conduction were
found in two patients. In patients with no neuropsychiatric
symptoms, ﬁve (42%) had abnormalities in SSEP, VEP and
BAEP.
Abnormal BAEP was signiﬁcantly more frequent in the
older age group as shown in prolonged wave L2 latency
(p= 0.4) and prolonged interpeak intervals 1-V and 111-V
(p= 0.00, p= 0.01, respectively). Moreover, BAEP wave L4
latency was signiﬁcantly more prolonged in patients with long-
er disease duration (p= 0.015).
There was no statistical signiﬁcant correlation between indi-
vidual neurophysiological disorders and speciﬁc neuropsychi-
atric symptoms. Moreover, there was no signiﬁcant
correlation between abnormal electrophysiologic ﬁndings and
SLE related auto antibodies.
Discussion
In the present study, there was no statistical signiﬁcant corre-
lation between abnormal radiological ﬁndings in SWI and the
age of the patients and the duration of the disease. Csepany et
al.18 reported that no correlation was found between the MRI
ﬁndings and age of the patient at the time of the diagnosis and
the duration of SLE which means that involvement of the CNS
may occur any time during the course of SLE. In contrast,
Gonzales19 reported that CNS lesions in patients with SLE
were associated with patient age and with disease duration,
but the patients in their study were younger, the duration of
SLE was shorter. With the progress of the disease, the effect
of risk factors as age and hypertension might have more signif-
icant inﬂuence on the MRI ﬁndings.
SWI is a three dimensional velocity-compensated gradient
echo sequence that combines both magnitude information
(used in conventional MR images, including T2* GE with
phase information to accentuate the visibility of susceptible
foci such small veins and hemorrhage. Micro-hemorrhages
contain hemosiderin, which is paramagnetic relative to normal
tissue and leads to large variations in local magnetic ﬁelds and
a local reduction in T2*. The signal intensity loss is
proportional to the amount of hemosiderin present. SWI, with
its unique sensitivity to blood products and hemorrhage, is
well-suited to detect imaging changes consistent with cerebral
angiopathy.14–17
In the current study, abnormal radiological ﬁndings de-
tected by SWI in SLE are more common in patients with neu-
rological deﬁcits than those without and these abnormalities
are signiﬁcantly more frequent in the hypertensive patients.
Moreover, the distribution of the different SWI ﬁndings espe-
cially infarcts differed signiﬁcantly between hypertensive and
normotensive patients. The American College of Rheumatology
for NP-SLE provided case deﬁnitions for 19 neuropsychiatric
Figure 1 Female patient 42 years old suffering from SLE presented with neurologic deﬁcit. (A) Axial T2-weighted image, (B) axial
FLAIR images, (C) axial SWI revealed old sizable ischemic insult targeting the left temporo-parietal region with hemosiderin deposition
due to underlying vasculopathy.
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one of the most important complications of SLE.20,21
Various auto antibodies have been implicated in pathogen-
esis of NP-SLE including aCL and LA. In this study, 37% of
patients with SLE were PA positive. Abnormal aCL and LA
were more frequent in patients of cerebrovascular insult. How-
ever, there was no statistically signiﬁcant difference in the per-
centage of the patients with or without positive PA subtypes
and neuropsychiatric involvement.
In the present study, small sub cortical lesions <1 cm
detected in SWI were more frequent (10 out of 30) than larger
lesions (5 out of 30), and the presence of these lesions did not
signiﬁcantly correlate with the immunological status of the pa-
tients. In this context, several studies found that the frequency
of increased serum level of aCL was higher in patients with ac-
tive NP-SLE compared to those without CNS affection.22,23
Case studies of patients with antiphospholipid syndrome
and lupus have demonstrated microscopic infarcts of the cor-
tical gray matter and fresh and recanalized thrombi with ﬁbro
muscular webs of the leptomeningeal arteries.24 This type of
CNS involvement might remain unrecognized by MRI because
of limited resolution of the examination. The small sub cortical
lesions might be related to vessel wall changes caused by eitherSLE itself or hypertension whereas the larger infarcts associated
with PA of thrombotic origin result in unique vascuolop-
athy.25,26 Many studies suggest that this unique vasculopathy
seen in SLE is highly associated with PA antibodies.27,28
In the present study, 19 patients (63%) had within normal
serum PA although the majority of them had abnormal evoked
potential parameters implying that these SLE related auto
antibodies may not be involved in the pathogenesis of abnor-
mal electrophysiological ﬁndings in the subclinical NP-SLE.
Mowaffak et al.29 studied 20 patients with SLE and they
reported that almost all patients with SLE (except two) had
within normal serum aCL level although all except one had
abnormal motor evoked potential parameters. Also, they con-
cluded that the normal levels of the assessed antibodies in the
study pointed out to their negligible pathogenic contribution
to the motor evoked potential changes in neurologically
asymptomatic patients.
Similarly, Ainiala et al.30 stated that the motor evoked
potential abnormalities are most probably related to brain
ischemia due to small vessel vasculopathy not mediated by
SLE related auto antibodies.
From the current study, it can be concluded that electro-
physiological studies can be a useful tool to detect subtle
Figure 2 Male patient 41 years old suffering from SLE presented with neurological deﬁcit. (A) Axial T1-weighted image, (B) axial
FALIR image, (C) axial T2-weighted image, (D) SWI image revealed sizable ischemic insult targeting the right temporo-parietal region
with hemosiderin deposition elicited on SWI.
Table 2 Radiological changes associated with phospholipid antibodies.
SWI PA- aCL Ig G+ aCL Ig M+ LA+
N= 19 N= 8 N= 4 N= 6
Normal NO 10 2 2 2
% 52.6 25.0 50.0 33.3
Atrophy NO 2 0 0 0
% 10.5 0 0 0
Infarct NO 2 2 1 2
% 10.5 25.0 25.0 33.3
SSCL NO 4 3 0 2
% 21.1 37.5 0 33.3
SSCL and infarct NO 0 1 1 0
% 0 12.5 25.0 0
SSCL and atrophy NO 1 0 0 0
% 5.3 0 0 0
SSCL: small subcortical lesions, infarcts larger than 10 mm lesions.
PA: antiphospholipid.
aCL IgG/IgM: anticardiolipin immunoglobulin G, M.
LA: lupus anticoagulant.
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However, to conﬁrm its efﬁciency and reliability as a screening
tool, it should be compared with one of the MRI techniques
that detects CNS involvement at the microscopic level.
Detecting electrophysiological abnormalities in neurologically
asymptomatic SLE patients should improve treatment deci-
sions and management.Therefore, we suggest performing the SWI and electrophys-
iological studies in SLE patients, even in the asymptomatic
ones, early in the course of the disease in order to detect the
CNS involvement.
In our study, the presence of neurophysiological and radio-
logical abnormalities in neurologically asymptomatic patients
may have a value in early detection of the neuropsychiatric
Table 3 Comparison between SLE patients and controls
regarding evoked potential parameters.
Patient group Control group P
SSEP
Latency (ms) 20.21 ± 3.65 19.84 ± 0.98 0.658
Amplitude (uv) 3.04 ± 0.89 5.78 ± 1.64 0.048*
VEP
Latency (ms) 130.03 ± 166.37 98.98 ± 2.7 0.022*
Amplitude (uv) 9.36 ± 2.69 12.61 ± 4.73 0.043*
BS auditory EP (wave latency/ms)
L1 2.01 ± 1.15 1.64 ± 0.25 0.048*
L2 2.94 ± 0.22 2.74 ± 0.22 0.522
L3 4.69 ± 1.30 3.89 ± 0.21 0.107
L4 5.47 ± 0.41 5.06 ± 0.27 0.336
L5 6.33 ± 0.36 5.75 ± 0.30 0.277
BAEP (interpeak latency/ms)
I–III 2.95 ± 0.40 2.17 ± 0.37 0.582
I–V 4.79 ± 0.35 4.11 ± 0.38 0.692
III–V 2.57 ± 0.42 1.86 ± 0.27 0.042*
SSEP: somatosensory evoked potential.
VEP: visual evoked potential.
BAEP: brain stem auditory evoked potential.
* P value <0.05 was considered statistically signiﬁcant.
170 H.M. Saad Allah et al.manifestations. If these observations are extended and con-
ﬁrmed, SWI and neurophysiological studies may provide a
useful test to the clinician in the evaluation and management
of neurological lupus.
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